Výsledky vyhledávání - "Manoj Maniar"

Akademický článek

Serum microRNA profile of rhesus macaques following ionizing radiation exposure and treatment with a medical countermeasure, Ex-Rad

Autor: Eric Russ, Oluseyi O. Fatanmi, Stephen Y. Wise, Alana D. Carpenter, Manoj Maniar, Sergey Iordanskiy, Vijay K. Singh

Publikováno v: Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)

Abstract Exposure to ionizing radiation (IR) presents a formidable clinical challenge. Total-body or significant partial-body exposure at a high dose and dose rate leads to acute radiation syndrome (ARS), the complex pathologic effects that arise fol

Externí odkaz: https://doaj.org/article/f8b341f1621c4f83a95e9eda4d72246c

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Analysis of the metabolomic profile in serum of irradiated nonhuman primates treated with Ex-Rad, a radiation countermeasure

Autor: Yaoxiang Li, Michael Girgis, Stephen Y. Wise, Oluseyi O. Fatanmi, Thomas M. Seed, Manoj Maniar, Amrita K. Cheema, Vijay K. Singh

Publikováno v: Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)

Abstract To date, the United States Food and Drug Administration (FDA) has approved four drugs to mitigate hematopoietic acute radiation syndrome and all four are repurposed radiomitigators. There are several additional drug candidates currently unde

Externí odkaz: https://doaj.org/article/80b88c81ca084e9ba1188c3b3a5941af

Zobrazit plný text záznamu

Analysis of the Proteomic Profile in Serum of Irradiated Nonhuman Primates Treated with Ex-Rad, a Radiation Medical Countermeasure

Autor: Alana D. Carpenter, Yaoxiang Li, Brianna L. Janocha, Stephen Y. Wise, Oluseyi O. Fatanmi, Manoj Maniar, Amrita K. Cheema, Vijay K. Singh

Publikováno v: Journal of Proteome Research. 22:1116-1126

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cb72e88781a75c836076962eefe8c5a2
https://doi.org/10.1021/acs.jproteome.2c00458

Zobrazit plný text záznamu

Data from Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies

Purpose: To determine the pharmacokinetics (PK), maximum tolerated dose (MTD), safety, and antitumor activity of an oral formulation of rigosertib, a dual phosphoinositide 3-kinase (PI3K) and polo-like kinase 1 (Plk1) pathway inhibitor, in patients w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5821806c41159b147bc979b7d3495244
https://doi.org/10.1158/1078-0432.c.6522141.v1

Zobrazit plný text záznamu

Supplementary Figure 1 from Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer

Autor: Antonio Jimeno, Alex A. Adjei, S. Gail Eckhardt, Francois Wilhelm, Manoj Maniar, Chen Ren, Amy Whitworth, Colin D. Weekes, Grace K. Dy, Wells A. Messersmith, Wen Wee Ma

PDF file - 49K

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d0acd224e6800f7d570a643e54c6c48
https://doi.org/10.1158/1078-0432.22443432

Zobrazit plný text záznamu

Supplementary Figure Legend 1 from Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer

Autor: Antonio Jimeno, Alex A. Adjei, S. Gail Eckhardt, Francois Wilhelm, Manoj Maniar, Chen Ren, Amy Whitworth, Colin D. Weekes, Grace K. Dy, Wells A. Messersmith, Wen Wee Ma

PDF file - 36K

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e710c0c5b5b6f37aeb6ec9567fd41a9
https://doi.org/10.1158/1078-0432.22443429.v1

Zobrazit plný text záznamu

Supplemental Methods, Figure 1,Tables 1-6 from Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies

Supplemental Figure S1: Supplemental Figure 1 shows the pharmacokinetic plasma concentration curve following a single dose of oral rigosertib, revealing dose-dependent pharmacokinetics; Supplemental Table S1: This file provides individual patient cha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6aba3c32b70b6fb714ad732fb1c09e2
https://doi.org/10.1158/1078-0432.22451247.v1

Zobrazit plný text záznamu

Data from Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer

Autor: Antonio Jimeno, Alex A. Adjei, S. Gail Eckhardt, Francois Wilhelm, Manoj Maniar, Chen Ren, Amy Whitworth, Colin D. Weekes, Grace K. Dy, Wells A. Messersmith, Wen Wee Ma

Purpose: Rigosertib, a dual non-ATP inhibitor of polo-like kinase 1 (Plk1) and phosphoinositide 3-kinase pathways (PI3K), and gemcitabine have synergistic antitumor activity when combined in preclinical studies. This phase I study aimed to determine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e91d6e319a97772128d9f70b7aee548
https://doi.org/10.1158/1078-0432.c.6519816.v1

Zobrazit plný text záznamu

Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study

Autor: Shyamala C. Navada, Patrick S. Zbyszewski, Richard C. Woodman, Naveen Pemmaraju, Rosmy B. John, Guillermo Garcia-Manero, Lewis R. Silverman, Erin P. Demakos, Rosalie Odchimar-Reissig, Steven M. Fruchtman, Maro Ohanian, Yesid Alvarado, Manoj Maniar

Publikováno v: Leukemia research. 94

Phase 1 results from a Phase 1/2 study comprise 18 patients with myelodysplastic syndromes (MDS; n = 9), acute myeloid leukemia (AML; n = 8), and chronic myelomonocytic leukemia (CMML; n = 1) who were either hypomethylating agent naive (n = 10) or re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdd5bd23ecb36503901cee3ce395699a
https://pubmed.ncbi.nlm.nih.gov/32442785

Zobrazit plný text záznamu

Effect of β-cyclodextrin and Hydroxypropyl β-cyclodextrin on Aqueous Stability, Solubility and Dissolution of Novel Anti-cancer Drug Rigosertib

Autor: Hardikkumar H. Patel, Manoj Maniar, Rutesh H. Dave, Chen Ren, Maitri R. Trivedi

Publikováno v: Journal of Pharmaceutical Research International. 21:1-20

Aim: To study Effect of β-cyclodextrin and hydroxypropyl β-cyclodextrin on aqueous stability, solubility and dissolution of novel anti-cancer drug Rigosertib. Methods: β-cyclodextrin and hydroxypropyl β-cyclodextrin were used to form complex with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8911cc9262c1d6a6f50489ef57129e7c
https://doi.org/10.9734/jpri/2018/39890

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání